Paul Hicks - Texas A&M University (TAMU) Scholar

HR job title

Retired Professor

selected publications

academic article
- Zisook, S., Johnson, G. R., Hicks, P., Chen, P., Beresford, T., Michalets, J. P., ... Mohamed, S (2021). Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report. DEPRESSION AND ANXIETY. 38(2), 185-195.
- Mohamed, S., Johnson, G. R., Sevilimedu, V., Rao, S. D., Hicks, P. B., Chen, P., ... CSP#576 VAST-D Investigators (2020). Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. J Clin Psychiatry. 81(4),
- Hicks, P. B., Sevilimedu, V., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., ... Zisook, S (2019). Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report. Psychiatric Research and Clinical Practice. 1(2), 58-67.
- Zisook, S., Johnson, G. R., Tal, I., Hicks, P., Chen, P., Davis, L., ... Mohamed, S (2019). General Predictors and Moderators of Depression Remission: A VAST-D Report. Am J Psychiatry. 176(5), 348-357.
- Mohamed, S., Johnson, G. R., Chen, P., Hicks, P. B., Davis, L. L., Yoon, J., ... Little, J. T (2017). Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA: Journal of the American Medical Association. 318(2), 132-145.
- Zisook, S., Tal, I., Weingart, K., Hicks, P., Davis, L. L., Chen, P., ... Mohamed, S (2016). Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report. J Affect Disord. 206, 232-240.
- Krystal, J. H., Pietrzak, R. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J., Jones, K. M., ... Veterans Affairs Cooperative Study #504 Group (2016). Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. J Clin Psychiatry. 77(4), 483-491.
- Mohamed, S., Johnson, G. R., Vertrees, J. E., Guarino, P. D., Weingart, K., Young, I. T., ... Zisook, S (2015). The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research. 229(3), 760-770.
- Leatherman, S. M., Liang, M. H., Krystal, J. H., Lew, R. A., Valley, D., Thwin, S. S., Rosenheck, R. A., & CSP 555 Investigators (2014). Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. JOURNAL OF NERVOUS AND MENTAL DISEASE. 202(1), 13-17.
- Young, K. A., Holcomb, L. A., Yazdani, U., Hicks, P. B., & German, D. C (2004). Elevated neuron number in the limbic thalamus in major depression. Am J Psychiatry. 161(7), 1270-1277.
- Young, K. A., Smith, M., Rawls, T., Elliott, D. B., Russell, I. S., & Hicks, P. B. (2001). N100 evoked potential latency variation and startle in schizophrenia. NeuroReport.
- Wadenberg, M. L., & Hicks, P. B (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neuroscience & Biobehavioral Reviews. 23(6), 851-862.
- Jeste, D. V., Klausner, M., Brecher, M., Clyde, C., & Jones, R (1997). A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting. Psychopharmacology. 131(3), 239-247.
- Hicks, P., Young, K., & Zavodny, R (1993). Further evidence for a 5-HT-1C modulation of apomorphine-induced locomotor activity. Schizophr Res. 9(2-3), 238-238.
- Hicks, P. B (1990). The effect of serotonergic agents on haloperidol-induced catalepsy. LIFE SCIENCES. 47(18), 1609-1615.
- Hicks, P. B., Vinogradov, S., Riney, S. J., Su, K., & Csernansky, J. G (1989). A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics. J Clin Psychopharmacol. 9(3), 209-212.
- Hicks, P., Rolsten, C., Brizzee, D., & Samorajski, T (1983). Age-related changes in rat brain capillaries. Neurobiol Aging. 4(1), 69-75.
- Misra, C. H., Hicks, P., Rolsten, C., Smith, R. C., & Schoolar, J. C (1982). Regional uptake of [35S]-cysteine in rat brain after arterial injection. Res Commun Chem Pathol Pharmacol. 37(1), 155-158.
- Rolsten, C., Hicks, P., Samorajski, T., & Schoolar, J (1982). Decreased response latency time of aged C57BL/6J male mice to benzodiazepines. 5(4), 146-147.
- Strong, R., Hicks, P., Hsu, L., Bartus, R. T., & Enna, S. J (1980). Age-related alterations in the rodent brain cholinergic system and behavior. Neurobiol Aging. 1(1), 59-63.
- Smith, R. C., Strong, J. R., Hicks, P. B., & Samorajski, T (1979). Behavioral evidence for supersensitivity after chronic bromocriptine administration. Psychopharmacology. 60(3), 241-246.
- Strong, R., Smith, R., & Hicks, P (1978). Increased behavioral effects of dopamine agonists in aged rodents. PHARMACOLOGIST. 20(3),
chapter
- Smith, C. M., Hicks, P. B., Lindefjeld, J. K., Taylor, B. M., Fisher, D. R., Faragon, J. J., ... Cozza, K. L (2022). Antiretrovirals and Psychotropics: Drug Interactions and Complications. HIV Psychiatry. (pp. 415-476). Springer International Publishing.
conference paper
- Young, K. A., Bonkale, W., Sachsenmaier, S., & Hicks, P. (2009). VA/VL THALAMIC CELL NUMBER IN SCHIZOPHRENIA AND MOOD DISORDERS. Schizophrenia Bulletin. 226-227.
- Young, K. A., Holcomb, L. A., Bonkale, W. L., & Hicks, P. B. (2007). Normal oligodendrocyte cell numbers in anterior thalamus in schizophrenia Normal oligodendrocyte cell numbers in anterior thalamus in schizophrenia. Schizophrenia Bulletin. 274-274.
- Schubert, M. H., Young, K. A., Justice, S. B., Durgam, S. K., Schmitz, W. M., House, M. D., & Hicks, P. B (2005). Cognitive improvement in schizophrenia and schizoaffective disorder by augmentation of risperidone with galantamine. Schizophrenia Bulletin. 503-503.
- Browning, J. L., Young, K. A., & Hicks, P. B (2005). The MEK/ERK map kinase pathway in antipsychotic actions. Schizophrenia Bulletin. 296-296.
- German, D., Yazdani, U., Hicks, P., & Young, K (2004). Increased number of neurons in the limbic thalamus in major depressive disorder. BIOLOGICAL PSYCHIATRY. 84S-84S.
- Hicks, P. B., Browning, J. L., Schubert, M. H., & Young, K. A (2003). 5-HT2A antagonism does not affect catalepsy in rats. Schizophr Res. 356-357.
- Browning, J. L., Young, K. A., Holcomb, L. A., Jones, D. H., & Hicks, P. B (2003). The role of the map kinase ERK pathway in the antipsychotic actions of clozapine. Schizophr Res. 309-309.
- Young, K. A., Skol, A. S., Tsuang, D. W., Faraone, S. V., Bingham, S., Prabhudesai, S., ... Tsuang, M. T. (2003). Association of NOTCH4 with schizophrenia in VA coop study #366. Schizophr Res. 92-92.
- Holcomb, L. A., Hicks, P. B., Metz, D. S., Stepp, S., & Young, K. A. (2001). Anterior thalamic volume in schizophrenia and mood disorders. Schizophr Res. 61-61.
- Young, K. A., Russell, I. S., & Hicks, P. B. (2001). Changes in evoked potential latency variation over time are associated with changes in EP and startle gating in schizophrenic patients. Schizophr Res. 126-126.
- Browning, J. L., Patel, T., Brandt, P. C., Young, K. A., & Hicks, P. B. (2001). Is the mechanism of action of antipsychotic agents mediated through the MAP kinase signal transduction system?. Schizophr Res. 87-88.
- Hicks, P. B., Browning, J., Barwick, S., Jones, D., Wadenberg, M. L., Richter, J. T., & Young, K. A (1999). M100,907 acts at both the nucleus accumbens and the prefrontal cortex to mediate the enhancement of the suppression of conditioned avoidance response by haloperidol. Schizophr Res. 115-115.
- Holcomb, L. A., Manaye, E. F., German, D. C., Hicks, P. B., & Young, K. A. (1999). GFAP and Rab3a immunoreactivity in the thalamus of schizophrenics. Schizophr Res. 81-81.
- Young, K. A., Smith, M., Clark, W., Hicks, P. B., & Russell, I. S. (1999). Incidence of startle prepulse inhibition deficits in schizophrenics. Schizophr Res. 188-188.
- Barwick, V. S., Manaye, K. F., Brandt, A., German, D. C., Hicks, P. B., & Young, K. A. (1999). Stereological estimate of total thalamic neuron number in schizophrenics. Schizophr Res. 79-79.
- Wadenberg, M., Hicks, P. B., Young, K. A., & Travis Richter, J (1997). Further evidence for a role of the 5-HT2A receptor in the mediation of antipsychotic activity. Schizophr Res. 83-83.
- Young, K. A., Denise Brady, M., & Hicks, P. B. (1995). Psychophysiological evidence for neuroleptic-induced depolarization block in schizophrenics. Schizophr Res. 170-171.

principal investigator on

IPA for Jeffrey Browning awarded by Central Texas Veterans Health Care System - (Waco, Texas, United States) 2017 - 2018

education and training

M.D. in Medicine, Baylor College of Medicine - (Houston, Texas, United States) 1983
Ph.D. in Pharmacology, Baylor College of Medicine - (Houston, Texas, United States) 1983
Stanford Medicine - (Stanford, California, United States) , Medical Residency 1987
Baylor College of Medicine - (Houston, Texas, United States) , Medical Residency 1984

first name

Paul

has last name

Hicks

mailing address

Texas A&M Health Science Center

Instructional Admin

1114 TAMUS

Temple, TX 76508

USA

email

phicks@tamu.edu

Hicks, Paul Professor

Positions

Overview

HR job title

Publications

selected publications

academic article

chapter

conference paper

Research

principal investigator on

Background

education and training

Contact

first name

has last name

mailing address

Other

email